Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Timothy S. Lewis"'
Autor:
Sharsti Sandall, Timothy S. Lewis, Robert Lawrence, Rachael Hu, Kelly M. Hensley, Sean Allred, Albina Nesterova, Disha Sahetya, Ivan J. Stone, Steven Jin, Roma Yumul, Nicole M. Okeley, Julia H. Cochran, Liem T. Nguyen, Markus Carlson, Christopher I. Leiske, Thomas A. Pires, Lori Westendorf, Christopher Hale, Robert Thurman, Devra J. Olson, John J. Gosink, Marsha L. Mason, Rebecca Mazahreh
Tables S1-S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f12f4d6de72d7298f62dd976fda384
https://doi.org/10.1158/1535-7163.22551993
https://doi.org/10.1158/1535-7163.22551993
Autor:
Sharsti Sandall, Timothy S. Lewis, Robert Lawrence, Rachael Hu, Kelly M. Hensley, Sean Allred, Albina Nesterova, Disha Sahetya, Ivan J. Stone, Steven Jin, Roma Yumul, Nicole M. Okeley, Julia H. Cochran, Liem T. Nguyen, Markus Carlson, Christopher I. Leiske, Thomas A. Pires, Lori Westendorf, Christopher Hale, Robert Thurman, Devra J. Olson, John J. Gosink, Marsha L. Mason, Rebecca Mazahreh
Figures S1-S9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95040322453266a34a57f4235635b823
https://doi.org/10.1158/1535-7163.22551999
https://doi.org/10.1158/1535-7163.22551999
Autor:
Sharsti Sandall, Timothy S. Lewis, Robert Lawrence, Rachael Hu, Kelly M. Hensley, Sean Allred, Albina Nesterova, Disha Sahetya, Ivan J. Stone, Steven Jin, Roma Yumul, Nicole M. Okeley, Julia H. Cochran, Liem T. Nguyen, Markus Carlson, Christopher I. Leiske, Thomas A. Pires, Lori Westendorf, Christopher Hale, Robert Thurman, Devra J. Olson, John J. Gosink, Marsha L. Mason, Rebecca Mazahreh
SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of a humanized antibody, hL49, with high specificity an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b77206f339225f16ad5ec99c26106011
https://doi.org/10.1158/1535-7163.c.6534823.v1
https://doi.org/10.1158/1535-7163.c.6534823.v1
Autor:
Dennis R. Benjamin, Eric J. Feldman, Che-Leung Law, Peter D. Senter, Sa A. Wang, Maitrayee Goswami, Timothy S. Lewis, Mechthild Jonas, Weiping Zeng, Ivan J. Stone, Martha E. Anderson, Michelle Ulrich, Kerry Klussman, Django Sussman, Ashley Cronkite, Lucy Pan, John Valliere-Douglass, Lori Westendorf, Roland B. Walter, Changpu Yu, May Kung Sutherland, Fu Li
Gating strategy, primary AML cytotoxicity assay,additional cell liens for pH2AX assay and caspase assay, and h7G3ec antibody sequence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d6621500ceec28e5ffa45ca4f5d714e
https://doi.org/10.1158/1535-7163.22505200
https://doi.org/10.1158/1535-7163.22505200
Autor:
Dennis R. Benjamin, Eric J. Feldman, Che-Leung Law, Peter D. Senter, Sa A. Wang, Maitrayee Goswami, Timothy S. Lewis, Mechthild Jonas, Weiping Zeng, Ivan J. Stone, Martha E. Anderson, Michelle Ulrich, Kerry Klussman, Django Sussman, Ashley Cronkite, Lucy Pan, John Valliere-Douglass, Lori Westendorf, Roland B. Walter, Changpu Yu, May Kung Sutherland, Fu Li
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, and there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac8020bf88554cef4d7229c4d038ea4f
https://doi.org/10.1158/1535-7163.c.6537988.v1
https://doi.org/10.1158/1535-7163.c.6537988.v1
Autor:
Sharsti Sandall, Timothy S. Lewis, Robert Lawrence, Rachael Hu, Kelly M. Hensley, Sean Allred, Albina Nesterova, Disha Sahetya, Ivan J. Stone, Steven Jin, Roma Yumul, Nicole M. Okeley, Julia H. Cochran, Liem T. Nguyen, Markus Carlson, Christopher I. Leiske, Thomas A. Pires, Lori Westendorf, Christopher Hale, Robert Thurman, Devra J. Olson, John J. Gosink, Marsha L. Mason, Rebecca Mazahreh
Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62f47ad3855a010481915e8deb0a354a
https://doi.org/10.1158/1535-7163.22495327
https://doi.org/10.1158/1535-7163.22495327
Autor:
Che-Leung Law, Iqbal S. Grewal, Julie A. McEarchern, Shang-Fan Yu, Jeffrey T. Lau, Kim Emmerton, Renee S. McCormick, Timothy S. Lewis
Purpose: Individually targeting B-cell antigens with monoclonal antibody therapeutics has improved the treatment of non-Hodgkin lymphoma (NHL). We examined if the antitumor activity of rituximab, CD20-specific antibody, could be improved by simultane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eae208fc48358573fb7580321035ac60
https://doi.org/10.1158/1078-0432.c.6519305.v1
https://doi.org/10.1158/1078-0432.c.6519305.v1
Autor:
Che-Leung Law, Iqbal S. Grewal, Julie A. McEarchern, Shang-Fan Yu, Jeffrey T. Lau, Kim Emmerton, Renee S. McCormick, Timothy S. Lewis
Supplementary Figures S1-S2 from Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5993b13a6a86ca42c451db75b8244257
https://doi.org/10.1158/1078-0432.22442630
https://doi.org/10.1158/1078-0432.22442630
Autor:
Timothy S. Lewis, Devra Olson, Margo Zaval, Robert Thurman, Shawna Hengel, Scott Peterson, Lauren Farr, Anita Kulukian, Janelle Taylor
Publikováno v:
Cancer Research. 80:P1-18
Background: Tucatinib is an orally administered, reversible HER2-targeted small molecule tyrosine kinase inhibitor that potently and selectively inhibits HER2 relative to the closely related kinase EGFR. In a phase Ib clinical trial in HER2+ metastat
Autor:
Ashley Cronkite, Peter D. Senter, Eric J. Feldman, Lucy Yan Pan, Maitrayee Goswami, Fu Li, May Kung Sutherland, Weiping Zeng, John F. Valliere-Douglass, Lori Westendorf, Michelle Ulrich, Che Leung Law, Sa A. Wang, Dennis Benjamin, Kerry Klussman, Changpu Yu, Django Sussman, Roland B. Walter, Ivan Stone, Timothy S. Lewis, Mechthild Jonas, Martha Anderson
Publikováno v:
Molecular Cancer Therapeutics. 17:554-564
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, and there